AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Siplizumab Safe And Well Tolerated In Clinical Trials.(Brief Article)
2001 JUL 25 - (NewsRx.com & NewsRx.net) --
MedImmune, Inc. (MEDI) and BioTransplant Incorporated (BTRN) announced results from three clinical trials with siplizumab, showing that the humanized monoclonal antibody is safe and well tolerated as therapy in psoriasis patients.
The initial clinical data were presented at the International Psoriasis Symposium and European Congress on Psoriasis, held in San Francisco, California, June 19-24, 2001.
Patients experienced improvement in psoriasis, as measured by PASI (Psoriasis Area and Severity Index) score via both intravenous and subcutaneous routes of administration. Further, preliminary follow-up data indicate that improvement in patients' psoriasis appears to be durable following completion of treatment.
"We are pleased that siplizumab appears to be safe and well tolerated and is having a clinically meaningful and durable impact on patients' psoriatic disease," said James F. Young, PhD, MedImmune. "We currently have a broad Phase II program underway and expect to provide additional data from our Phase I program later this year at the European Society of Dermatological Research Meeting to be held September 20-22, 2001 in Stockholm, Sweden."
Studies presented June 23, 2001 at the International Psoriasis Symposium included:
* A Phase I, open-label, single-dose, intravenous safety study involving 14 moderate-to-severe psoriasis patients who were given 0.0004 mg/kg, 0.0012 mg/kg, 0.004 mg/kg, or 0.012 mg/kg of siplizumab
- Psoriasis patients show improvement in phase II study of BG-12 oral fumarate.
- Newspaper article from: Drug Week May 28, 2004 700+ words
...fumarate, in patients with severe psoriasis. Patients who received BG-12 in the...patients with severe forms of psoriasis. Patients were equally randomized within...three different doses (120 mg, 360 mg, or 720 mg per day) for 12...
- Etanercept appears to ease psoriasis patients' depression.(Dermatologic Therapy)
- Magazine article from: Skin & Allergy News Splete, Heidi March 1, 2007 700+ words
...are common in psoriasis patients, according to...depressive symptoms in psoriasis patients being treated...to receive 50 mg etanercept or...prospective study of 86 psoriasis patients aged 18 years...combination of 50 mg etanercept twice...
- New Study Indicates That Psoriasis Patients Treated With Etanercept Show Rapid,...
- Press release article from: PR Newswire November 19, 2003 700+ words
...patients receiving 50 mg twice weekly of ENBREL...involved a total of 652 psoriasis patients who were randomized...dose of ENBREL (25 mg once weekly), medium...or high dose (50 mg twice weekly) for 12...results are exciting for psoriasis patients and show that ENBREL...
- New Study Indicates That Psoriasis Patients Treated With Etanercept Show Rapid,...
- Press release article from: PR Newswire November 20, 2003 700+ words
...patients receiving 50 mg twice weekly of ENBREL...involved a total of 652 psoriasis patients who were randomized...dose of ENBREL (25 mg once weekly), medium...or high dose (50 mg twice weekly) for 12...results are exciting for psoriasis patients and show that ENBREL...
- New Phase 3 ENBREL Data Show Psoriasis Patients Achieved a Therapeutic Response...
- Press release article from: PR Newswire February 9, 2004 700+ words
...significant number of psoriasis patients given initial loading...placebo (n=193), 25 mg of ENBREL twice weekly...a loading dose of 50 mg of ENBREL twice weekly...of patients taking 25 mg twice weekly and three...the loading dose." Psoriasis Patients Treated with ENBREL...
- DATA SHOWS ENBREL GAVE PSORIASIS PATIENTS BENEFIT AFTER DOSE CUT.
- News wire article from: Asia Africa Intelligence Wire June 30, 2005 700+ words
...etanercept) provided psoriasis patients with more rapid improvement...weeks when the highest dose (50 mg twice weekly) was used, compared to a continuous 25-mg twice-weekly dose. When the...half at week 12 in the 50-mg twice-weekly group, efficacy...
- Psoriasis Patients Show Significant Improvement in Symptoms with Abbott's...
- Press release article from: PR Newswire February 2, 2007 700+ words
...PRNewswire-FirstCall/ -- Psoriasis patients experienced a significant...promising potential treatment for psoriasis patients." About the REVEAL Study...receive either HUMIRA (40 mg every other week beginning...after a starting dose of 80 mg at week zero) or placebo...
- New Phase II Data Shows Improvement in Disease Activity and Quality of Life for...
- Press release article from: PR Newswire February 18, 2005 700+ words
...Academy of Dermatology (AAD) Psoriasis patients receiving HUMIRA(R) (adalimumab...patients receiving HUMIRA 40 mg every other week (eow) experienced...of patients taking HUMIRA 40 mg eow achieved at least a 75 percent...of patients taking HUMIRA 40 mg eow achieved PASI 90 -- a measurement...
- Diet increases effect of low-dose cyclosporine in psoriasis patients.(News)
- Magazine article from: Skin & Allergy News Jancin, Bruce November 1, 2007 700+ words
...All were placed on 2.5 mg/kg per day of cyclosporine...dosage to maintain it at 2.5 mg/kg. A PASI-75 assessed...protein levels in the obese psoriasis patients were elevated at baseline...JANCIN Denver Bureau Obese Psoriasis Patients Who Achieved a PASI-75...
- Diet plus low-dose cyclosporine very effective in obese psoriasis...
- Magazine article from: Internal Medicine News Jancin, Bruce February 15, 2008 700+ words
...more. All were placed on 2.5 mg/kg per day of cyclosporine, even though doses of less than 3 mg/kg are known to have poor...dosage to maintain it at 2.5 mg/kg. A PASI-75 was achieved...protein levels in the obese psoriasis patients were elevated at baseline and...
Source: HighBeam Research, Siplizumab Safe And Well Tolerated In Clinical Trials.(Brief Article)